Article Information
History
- May 11, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Patrick Harrington1,2,*,
- Hugues de Lavallade1,2,3,
- Katie J. Doores4,
- Amy O’Reilly1,
- Jeffrey Seow4,
- Carl Graham4,
- Thomas Lechmere4,
- Deepti Radia1,
- Richard Dillon1,5,
- Yogita Shanmugharaj1,
- Andreas Espehana1,
- Claire Woodley1,
- Jamie Saunders1,
- Natalia Curto-Garcia1,
- Jennifer O’Sullivan1,
- Kavita Raj1,
- Shahram Kordasti1,2,
- Michael H. Malim4,
- Claire Harrison1,2 and
- Donal McLornan1,2
- 1Department of Clinical Haematology, Guy’s & St Thomas’ NHS Foundation Trust, London, U.K.
- 2School of Cancer and Pharmaceutical Science, King’s College London. London, U.K.
- 3Department of Haematological Medicine, King’s College London School of Medicine, London, UK
- 4Department of Infectious Diseases, School of Immunology & Microbial Sciences, King’s College London, London, UK
- 5Department of Medicine and Molecular Genetics, King’s College London, London. U.K.
- ↵*Corresponding author; email: patrick.harrington{at}gstt.nhs.uk
Posted May 11, 2021.
Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms
